Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
Mark Crowther, Distinguished University Professor and Chair, Department of Medicine at McMaster University, shared on LinkedIn:
”McMaster’s Department of Medicine: New Insight into a Life-Threatening Blood Disorder, Led by McMaster Researchers
A paper published last week in the New England Journal of Medicine has reshaped how we understand heparin-induced thrombocytopenia (HIT)—a serious reaction to a widely used blood thinner.
Researchers from McMaster Faculty of Health Sciences and the McMaster University Department of Medicine have found that, contrary to decades of belief, a single monoclonal antibody is responsible for triggering HIT.
This key discovery suggests the condition is not a polyclonal immune response, as previously thought, but rather driven by one dominant antibody—an insight that could significantly improve diagnostic precision and lead to more targeted therapies.
The study was led by Dr. Ishac Nazy, PhD, Professor in the Department of Medicine and John G. Kelton Chair in Immunological Blood Disorders and and Dr Donald Arnold.
Their team includes investigators from the McMaster Platelet Immunology Laboratory and the Michael G. DeGroote Centre for Transfusion Research.
Dr. Nazy notes: ‘Our findings correct a long-standing misunderstanding of HIT and point toward more accurate and safer testing methods.’
This work underscores McMaster’s continued leadership in translational research—bringing molecular discoveries closer to clinical application.”
Find more insights here.
Stay updated on the emerging in the field of platelet disorders with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
